Irrelevance is an intractable opponent. If your grandparents grew up in a major city, talk to them about what the neighborhoods used to look like. Chances are there were certain staples like a neighborhood butcher shop, a neighborhood bakery, a neighborhood dry goods store and a local bar (or three). A lot of this has frankly disappeared over the years, and Walgreen (NYSE:WAG) needs to be creative and aggressive if it is going to stay relevant in a landscape where the core drug business is increasingly moving out of drugstores. (For more on retail stores, read The 4 R's Of Investing In Retail.)

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

An Okay End to the Fiscal Year
Walgreen's fiscal fourth quarter results were solid but a bit confusing, as a lower tax rate and share count did help boost reported earnings per share. Sales rose more than 6% on better than 4% comps, putting Walgreen ahead of other drugstore rivals CVS Caremark (NYSE:CVS) and Rite Aid (NYSE:RAD) in terms of sales momentum. Drug sales were up about a percentage point less than overall sales, but the comp sales were similar, and prescription drugs are still about two-thirds of the sales base.

Matters get a little more complicated below the top line. Gross margin fell again - this time by about 20 basis points - on lower front-end margins. Some of this could be a byproduct of more aggressive promotional efforts. The company did relatively well on SG&A, though, and operating income grew more than 11% as operating margin improved about 20 basis points.

Playing Chicken Versus Express Scripts
One of the darkest clouds over Walgreen is the ongoing dispute with Express Scripts (Nasdaq:ESRX). In short, Walgreen has decided to leave the ESRX network on January 1 unless Express Scripts changes (which means "increases" in this case) how it compensates Walgreen. Walgreen feels that it offers a host of value-added services that Express Scripts is not compensating it for fairly.

This is a risky move for Walgreen. The drugstore has at least $5 billion in prescription revenue at risk from this move, not to mention profitable ancillary revenue that comes when a customer goes to Walgreen to grab a prescription and leaves with a gallon of milk, toothpaste or a six-pack of beer. With those sales, then, also go gross profit and SG&A leverage. Making matters worse is the fact that Express Scripts could turn to CVS as a replacement (even notwithstanding the competition in the PBM business).

Can Walgreen squeeze better terms out of Express Scripts? It's going to be a difficult argument. Express Scripts is maintaining that Walgreen needs it more than it needs Walgreen, and that may be correct - especially with the impending acquisition of Medco (NYSE:MHS). On the flip side, maybe Walgreen can spin this as an example of Express Scripts trying to bully it and evidence that the acquisition of Medco should be blocked by the government. If Walgreen can get any traction with that argument, Express Scripts may see it as cheaper in the long run to simply buy off Walgreen with better terms. (To learn more about mergers and acquistions, read What Makes An M&A Deal Work?)

What's the Next Niche?
Longer term, there are some existential concerns about Walgreen. More and more drug sales are going through direct mail, and it's unclear that there's a sustainable niche here when Walgreen's primary advantage over the likes of Wal-Mart (NYSE:WMT) and Target (NYSE:TGT) seems to be in offering more SKUs of shampoo and make-up.

Still, don't count out Walgreen. Drugstores have been exceptionally adaptive over the years. Drugstores sold patent medicines (and legitimate drugs as well) before there even was a real pharmaceutical industry. Later, soda companies like Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) basically got their start through drugstore snack counters.

Who knows what could be next. Walgreen is already pushing service offerings like flu shots, and perhaps there's room to offer even more medical services through the pharmacies. In the meantime, at least the company has some major generic launches to look forward to, as Pfizer's (NYSE: PFE) Lipitor, Eli Lilly's (NYSE:LLY) Zyprexa and Forest Labs' (NYSE:FRX) Lexapro all face generic launches in the next six months (and each has had more than $2 billion in branded sales).

The Bottom Line
Walgreen's mission is straight forward - adapt or die. While Walgreen likely has a defensible niche as a small-footprint "general store" in dense urban areas, the company will have to be creative to make its stores relevant and sticky in suburban areas. Drugstores have always been surprisingly adaptive, though, so investors should not count out this company just yet. The challenges are formidable, but the stock is not too expensive, and management knows that it has a lot to prove before Wall Street will give them their due. (For more, read Analyzing Retail Stocks.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  2. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  3. Investing

    Don't Freak Out Over Black Swans; Be Prepared

    Could 2016 be a big year for black swans? Who knows? Here's what black swans are, how they can devastate the unprepared, and how the prepared can emerge unscathed.
  4. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  5. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  6. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  7. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  8. Stock Analysis

    Analyzing Sirius XM's Return on Equity (ROE) (SIRI)

    Learn more about the Sirius XM's overall 2015 performance, return on equity performance and future predictions for the company's ROE in 2016 and beyond.
  9. Stock Analysis

    Will Virtusa Corporation's Stock Keep Chugging in 2016? (VRTU)

    Read a thorough review and analysis of Virtusa Corporation's stock looking to project how well the stock is likely to perform for investors in 2016.
  10. Stock Analysis

    Analyzing Porter's Five Forces on JPMorgan Chase (JPM)

    Examine the major money-center bank holding firm, JPMorgan Chase & Company, from the perspective of Porter's five forces model for industry analysis.
RELATED FAQS
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center